A. E. Eskazan Et Al. , "Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.17, no.12, pp.804-811, 2017
Eskazan, A. E. Et Al. 2017. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.17, no.12 , 804-811.
Eskazan, A. E., Sadri, S., Keskin, D., Ayer, M., Kantarcioglu, B., Demirel, N., ... Aydin, D.(2017). Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.17, no.12, 804-811.
Eskazan, Ahmet Et Al. "Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.17, no.12, 804-811, 2017
Eskazan, Ahmet E. Et Al. "Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.17, no.12, pp.804-811, 2017
Eskazan, A. E. Et Al. (2017) . "Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.17, no.12, pp.804-811.
@article{article, author={Ahmet Emre EŞKAZAN Et Al. }, title={Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2017, pages={804-811} }